AegirBio AB Receives $239,547 award from the National Institutes of Health RADx Tech Program
As previously announced, AegirBio AB, a leading innovator in saliva-based diagnostics solutions, has received a phase 1 award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for an accessibility project for multiplex testing.Today, AegirBio has received funds of $239,547. This award, totaling up to $1.2 million, enables AegirBio AB to commence work towards their continued pursuit of advancements in the field of at-home self-testing. "We are honored to have received the first installment of the RADx Tech award," said Marco Witteveen, CEO